10-Q · May 7, 2026
Chiron Real Estate Inc. reported Q1 2026 results with strong earnings, boasting an EPS of $1.11, surpassing estimates significantly, while revenues slightly fell short of expectations at $38.02 million. Notably, the…
Earnings analysis · 10-Q
XRN earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results, so revenue, margins, EPS, working-capital trends and free cash flow cannot be assessed from…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results, so revenue, margins, EPS, working-capital trends and free cash flow cannot be assessed from the filing text supplied. The filing does show $96.8 million of net Series C proceeds used with cash and Credit Facility borrowings to fund acquisitions, but also highlights $141.0 million of unhedged variable-rate debt and approximately $1.4 million of annual cash-flow sensitivity per 100-basis-point SOFR increase. Sentiment is neutral because capital availability is positive but operating and financing risks are material and quarterly earnings trends are unavailable.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$96.8M net preferred-equity proceeds
The company completed a private placement of 1,000,000 shares of 6.00% Series C Convertible Preferred Stock for aggregate gross proceeds of $100.0 million and received approximately $96.8 million net of fees and expenses. Proceeds, cash on hand and Credit Facility borrowings funded acquisitions of the Landing and the Riviera.
-
Capital raised for acquisitions
As of June 30, 2026, the company had $141.0 million of unhedged variable-rate Revolver borrowings outstanding. The filing states that SOFR was 3.65% on June 30, 2026.
-
Controls assessed effective
Management states that disclosure controls and procedures were effective as of June 30, 2026, at a reasonable assurance level. The filing also reports no changes to internal control over financial reporting during the quarter that materially affected, or were reasonably likely to materially affect, those controls.
What to watch
-
Material floating-rate exposure
The company had $141.0 million of unhedged variable-rate borrowings as of June 30, 2026. A 100-basis-point increase in SOFR would decrease annual cash flow by approximately $1.4 million, assuming no increase in variable-rate debt.
-
Convertible preferred dilution
The Series C financing creates potential future common-stock dilution: 1,000,000 preferred shares are initially convertible at a rate of 2.32558 common shares per preferred share, based on an implied conversion price of $43.00 per common share. The preferred issuance generated $100.0 million of gross proceeds.
-
Expanded SHOP operating exposure
The 10-Q identifies new or expanded SHOP-related operational, licensing, manager-transition and litigation risks compared with the 2025 Annual Report, while stating that otherwise there were no material risk-factor changes. The company holds applicable healthcare licenses and may face penalties including loss or suspension of licenses, reimbursement denial or facility closure.
Management's outlook
The provided 10-Q extract does not include quantitative revenue or EPS guidance. No explicit numeric outlook is disclosed; guidance may have been provided in the earnings release or call.
Earlier filings 4
10-K · March 2, 2026
Chiron Real Estate (formerly Global Medical REIT) positions itself as a focused healthcare REIT investing in off‑campus and small-to-mid-sized medical facilities with a stated goal of delivering attractive dividends and…
10-Q · May 8, 2025
Global Medical REIT reported Q1 2025 total revenue of $34,618 (down from $35,118 in Q1 2024) and net income attributable to common stockholders of $2,104 (Q1 2024: $794), or $0.03 per share (Q1 2024: $0.01). Operating…
10-K · February 28, 2025
Global Medical REIT’s 2024 10-K emphasizes a strategy focused on decentralized healthcare real estate (primarily medical office buildings) and opportunistic investments while highlighting a new joint venture with…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.